Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Neurol Neurosurg Psychiatry ; 69(5): 595-600, 2000 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11032610

RESUMEN

OBJECTIVES: For Greece, data on incidence of stroke, type of stroke, and prognosis of stroke is limited. Recently, results on incidence of stroke were published. Here 1 year mortality, functional outcome after a first ever stroke, and determinants of the prognosis are described. METHODS: A population based registry was established in the Arcadia area, located in eastern central Peloponessos in southern Greece. Between 1 November 1993 and 31 October 1995, 555 patients with a first ever stroke were identified using information from death certificates, hospital records, public health centres and general practitioners. Extensive information on cardiovascular risk factors and stroke characteristics was obtained. After 1 year a modified Rankin score was determined in all surviving patients. RESULTS: After 1 year of follow up, 204 (36.8%) patients died. The probability of survival 1 year after stroke was higher for cerebral infarction than for intracerebral haemorrhage; 67.8% (95% confidence interval (95% CI) 64-72) and 46.4% (35-57), respectively. Of the survivors, 68.9% had either no symptoms or symptoms that would not interfere with their capacity to look after themselves (Rankin score 0 to 2). Increasing age and low Glasgow coma scale score were the most powerful predictors of death within 1 year (p<0.01), whereas increasing age, atrial fibrillation, and low Glasgow coma scale score were the most important predictors of functional outcome 1 year after a stroke (p<0.01). CONCLUSIONS: One year mortality from stroke in Greece is similar to that of other industrialised countries. The most important factors that affect the prognosis of a patient with a first ever stroke are increasing age, stroke severity, and atrial fibrillation.


Asunto(s)
Accidente Cerebrovascular/epidemiología , Accidente Cerebrovascular/fisiopatología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Grecia/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Sistema de Registros , Factores de Riesgo
2.
Cerebrovasc Dis ; 10(2): 133-41, 2000.
Artículo en Inglés | MEDLINE | ID: mdl-10686452

RESUMEN

The advent and wide application of new technology, especially noninvasive techniques, has enabled physicians to more completely investigate and clarify the etiopathogenic mechanisms of stroke. Such data have not been available until recently for Southeastern Europe. In addition, during the last decades, strategies for the modification of risk factors and primary prevention may have changed the prevalence of each subgroup of stroke as well. We investigated 1, 042 consecutive patients who had first strokes, during a period of 5 years (from June 1992 to May 1997) and classified them prospectively based on etiopathogenic mechanisms. Patients with transient ischemic attacks and subarachnoid hemorrhage were excluded. There were 613 male and 429 female patients, with a mean age of 70.2 +/- 11.9 years. Forty-six percent of the patients arrived within 3 h from stroke onset. The probable mechanisms were: large-artery atherosclerosis, 156 (15%); lacunes, 177 (17%); cardioembolic, 335 (32.1%); infarct of unknown cause, 182 (17.5%); miscellaneous causes, 35 (3.3%), and intracerebral hemorrhage (ICH), 157 (15.1%). In the cardioembolic group, nonvalvular atrial fibrillation (NVAF) was the probable cause in 225 patients, especially in patients older than 75 years (65%). The overall hospital mortality was 15.2% (from 0.6% for lacunar stroke to 34% for ICH). In our population, cardioembolism is the most frequent subtype of stroke. NVAF is the most likely source, especially in older patients.


Asunto(s)
Cardiopatías/complicaciones , Sistema de Registros , Accidente Cerebrovascular/etiología , Accidente Cerebrovascular/fisiopatología , Adulto , Anciano , Anciano de 80 o más Años , Arritmias Cardíacas/complicaciones , Hemorragia Cerebral/fisiopatología , Infarto Cerebral/etiología , Infarto Cerebral/fisiopatología , Enfermedad Coronaria/complicaciones , Femenino , Escala de Coma de Glasgow , Grecia , Enfermedades de las Válvulas Cardíacas/complicaciones , Humanos , Embolia Intracraneal/etiología , Masculino , Persona de Mediana Edad , Factores de Riesgo , Accidente Cerebrovascular/prevención & control , Índices de Gravedad del Trauma
3.
AJNR Am J Neuroradiol ; 18(9): 1661-8, 1997 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-9367313

RESUMEN

PURPOSE: To review our experience with intracranial angioplasty, including the complications we encountered. METHODS: During a 3-year period, from 1993 to 1996, 10 patients had intracranial percutaneous transluminal angioplasty (PTA). The stenosed vessels included three internal carotid arteries, one middle cerebral artery, one basilar artery, and five vertebral arteries. Stenosis in all patients was 75%, or greater. PTA was technically successful in eight patients; in two patients it could not be performed owing to inability to traverse the stenosed area. RESULTS: Two patients had successful and uneventful PTA. Five patients had vasospasm, which resolved with local vasodilators in two and with repeat PTA in one. Vasospasm led to stroke in two patients. Compromise of perforating vessels and arterial dissection were associated with stroke in two patients. CONCLUSION: Intracranial PTA is technically feasible but associated with risks related to vasospasm, arterial trauma, and compromise of perforating vessels.


Asunto(s)
Angioplastia de Balón/instrumentación , Isquemia Encefálica/terapia , Estenosis Carotídea/terapia , Arteriosclerosis Intracraneal/terapia , Insuficiencia Vertebrobasilar/terapia , Adulto , Anciano , Isquemia Encefálica/diagnóstico por imagen , Arteria Carótida Interna/diagnóstico por imagen , Estenosis Carotídea/diagnóstico por imagen , Angiografía Cerebral , Trastornos Cerebrovasculares/diagnóstico por imagen , Trastornos Cerebrovasculares/terapia , Femenino , Estudios de Seguimiento , Humanos , Arteriosclerosis Intracraneal/diagnóstico por imagen , Ataque Isquémico Transitorio/diagnóstico por imagen , Ataque Isquémico Transitorio/terapia , Masculino , Persona de Mediana Edad , Examen Neurológico , Insuficiencia del Tratamiento , Insuficiencia Vertebrobasilar/diagnóstico por imagen
4.
Stroke ; 27(8): 1333-7, 1996 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-8711797

RESUMEN

BACKGROUND AND PURPOSE: Cerebral amyloid angiopathy is an important cause of intracerebral hemorrhage in the elderly. The epsilon 4 allele of the apolipoprotein E gene, recently established as a genetic risk for Alzheimer's disease, has also been suggested as a possible risk factor for cerebral amyloid angiopathy. We sought to determine whether this allele is specifically associated with hemorrhages related to amyloid angiopathy and whether it correlates with the age at which first amyloid angiopathy-related hemorrhage occurs. METHODS: Forty-five consecutive patients presenting with lobar hemorrhage were prospectively classified according to clinical, radiological, and when available, pathological features and evaluated for apolipoprotein E genotype. They were compared with 1899 elderly patients from a population-based sample and with 18 consecutive patients with hemorrhages in deep regions typical of a hypertensive mechanism. RESULTS: Patients with multiple hemorrhages confined to the lobar territory demonstrated a greater than twofold overrepresentation (P < .001) in frequency of the apolipoprotein E epsilon 4 allele compared with the population-based sample. Apolipoprotein E genotypes of patients with hemorrhages in deep territories resembled the population sample. Among patients with strictly lobar hemorrhages, carriers of the epsilon 4 allele had their first hemorrhage more than 5 years earlier than noncarriers (mean age at first hemorrhage, 73.4 +/- 8.0 versus 78.9 +/- 7.4 years; P = .033). These effects were independent of the accompanying presence of Alzheimer's disease. CONCLUSIONS: The data support a specific role for apolipoprotein E epsilon 4 in accelerating the process that leads to amyloid angiopathy-related hemorrhage.


Asunto(s)
Apolipoproteínas E/genética , Angiopatía Amiloide Cerebral/genética , Hemorragia Cerebral/genética , Factores de Edad , Anciano , Alelos , Apolipoproteína E4 , Angiopatía Amiloide Cerebral/diagnóstico , Angiopatía Amiloide Cerebral/epidemiología , Hemorragia Cerebral/diagnóstico , Hemorragia Cerebral/epidemiología , Femenino , Frecuencia de los Genes , Genotipo , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Factores de Riesgo , Factores de Tiempo
5.
Clin Neuropharmacol ; 17(5): 454-9, 1994 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-9316695

RESUMEN

Weakness, easy fatiguing, and lack of endurance are commonly perceived by patients with Parkinson's disease (PD). Although the slowed motor repertoire in PD may underlie these experiences, other abnormalities in skeletal muscle utilization also may be involved. We investigated whether an index of metabolic efficiency during a continuous exercise task, the latency until anaerobic threshold (AT), is altered by L-DOPA (LD). While pedalling a bicycle ergometer against a uniform workload, subjects were monitored for expired O2 and CO2. As compared to an unmedicated state, LD treatment delayed AT by a mean (+/-SE) of 5.67 +/- 0.89 to 6.62 +/- 1.23 min (p < 0.05), paired t test). Subjects did not differ in their perceived exertion upon reaching AT. With relief of parkinsonism by LD, the efficiency of energy utilization is also increased in exercised skeletal muscle.


Asunto(s)
Antiparkinsonianos/uso terapéutico , Levodopa/uso terapéutico , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/fisiopatología , Enfermedad de Parkinson/tratamiento farmacológico , Enfermedad de Parkinson/fisiopatología , Esfuerzo Físico/fisiología , Adulto , Anciano , Prueba de Esfuerzo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Músculo Esquelético/metabolismo , Enfermedad de Parkinson/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA